We have previously described a set of mutants (16.23-selected mutants) of a B lymphoblastoid cell line that are defective in the presentation of intact proteins to class II-restricted T cells, but effectively present immunogenic peptides. The mutations in these mutants are recessive in somatic cell hybrids and are not in Class II structural genes. Here, we report on a unique mutant, 5.2.4, in which a similar defect in class II-restricted antigen presentation has occurred in association with a one-megabase homozygous deletion in the class II region of the major histocompatibility complex (MHC). The defects in class II presentation among three of the 16.23-selected mutants, and between these mutants and 5.2.4, are noncomplementary in somatic cell hybrids. This suggests that the class II presentation-defective phenotype in all four mutants results from lesions in a single MHC-linked gene, a conclusion strengthened by the finding that in a hybrid made with a second, unrelated MHC deletion mutant, T2, the class II presentation defect in a 16.23-selected mutant is also not complemented. Mutant 5.2.4, in addition to its class II presentation defect, is also defective in surface expression of MHC class I molecules, most likely because its deletion encompasses the peptide supply factor 1 gene, whose function is known to be required for normal abundance of cell surface class I molecules. However, the surface abundance of class I molecules is normal in the 16.23-selected mutants, suggesting that the lesions affecting class I surface abundance and class II presentation result from mutations in different genes. p resentation of an endocytosed protein antigen by APC requires that it be processed intracellularly into immunogenic peptide fragments, which become bound to MHC class II molecules (reviewed in reference 1). The complex of peptide and MHC molecule is transported to the APC surface, where it can be recognized by CD4 + T cells. This handling of foreign antigen is apparently part of a more general process in which class II molecules en route to the cell surface bind both foreign and self peptides. The majority of cell surface class II molecules are occupied by self-peptides (2). Nonetheless, this system provides effective immune surveillance of the extraceUular space, because occupancy of a small fraction of MHC class II molecules with immunogenic peptide is sufficient to activate specific T cells (3, 4).
p resentation of an endocytosed protein antigen by APC requires that it be processed intracellularly into immunogenic peptide fragments, which become bound to MHC class II molecules (reviewed in reference 1). The complex of peptide and MHC molecule is transported to the APC surface, where it can be recognized by CD4 + T cells. This handling of foreign antigen is apparently part of a more general process in which class II molecules en route to the cell surface bind both foreign and self peptides. The majority of cell surface class II molecules are occupied by self-peptides (2) . Nonetheless, this system provides effective immune surveillance of the extraceUular space, because occupancy of a small fraction of MHC class II molecules with immunogenic peptide is sufficient to activate specific T cells (3, 4) .
Previously, we used an anti-HLA-DK3 mAb, 16.23, to select a set of B-lymphoblastoid mutants (hereafter called 16.23-selected mutants) which define a novel step in class II-restricted antigen presentation (5, 6) . Unlike the progenitor cells, the mutants, exemplified by mutant 9.5.3, are unable to stimulate specific T cell clones when exposed to intact protein antigens. Their class II molecules effectively present exogenously supplied peptides, however. Thus, the mutants appear unable to form intracellular MHC class II-peptide complexes from intact protein antigens. The class II structural genes and the surface abundance of class II molecules in these mutants are normal. However, the mutants demonstrate a subtle change in class II molecule conformation. Their HLA-DK3 molecules have lost expression of the epitope recognized by antibody 16.23, and dass II dimers extracted from the mutants dissociate into monomers in SDS-PAGE, whereas dimers extracted from progenitor cells under the same conditions do not dissociate. We have proposed that these conformational changes are related to underoccupancy of cell surface class II molecules resulting from defective peptide loading during class II molecule biosynthesis. The amount of invariant chain (Ii), 1 its glycosylation, and the kinetics of its association and dissociation from DR molecules do not differ in mutant 9.5.3 and its progenitor, 8.1.6 (reference 6 and E. Mellins, unpublished data). These findings suggest that the DR-Ii complexes in the mutants traffic normally through the Golgi apparatus to the compartment where Ii dissociation occurs. The phenotypic features of the mutants thus implicate gene products other than class II molecules and Ii in the formation of MHC class II-peptide complexes.
Here, we report on an informative new mutant B lymphoblastoid cell line (B-LCL), 5.2.4, which was selected with an anti-DR mAb for loss of surface expression of DR molecules. In contrast to the 16.23-selected mutants, which are likely to be point mutants (reference 7 and D. Pious, unpublished data), mutant 5.2.4 has a homozygous deletion within the class II region of the MHC. Mutant 5.2.4 resembles the unrelated mutant human cell lines, 721.174 and T2 (8) (9) (10) , and the mutant murine line RMA-S (11) in that it has reduced surface abundance of class I molecules that can be increased by incubation of the cells with an appropriate peptide. However, 5.2.4 is unlike 721.174 and T2 in that it retains DP genes from one haplotype, allowing us to examine the function of its class II molecules. We find that deletion mutant 5.2.4 manifests the class II presentation-defective phenotype, and it is noncomplementary with several of the 16.23 selected mutants for the class II presentation defect. Further, the T2 cell line, which is homozygously deleted for a region of the MHC that includes the 5.2.4 deletion, does not complement the mutation in 9.5.3. These findings strongly suggest that defects in a gene(s) mapping within the MHC are responsible for the class II presentation-defective phenotype.
Materials and Methods
APC Lines. With the exception of the T2 cell line, the APC used in these studies are all derived from B-LCL T5-1 ( Fig. 1 a) . The hemizygous deletion mutants 8.1.6 and 9.28.6 were derived directly from T5-1, 8.1.6, by ethyl methane sulfonate (EMS) mutagenesis of T5-1 and selection with an HLA-DR1 antiserum and complement (12) , and 9.28.6, by mitomycin c mutagenesis and selection with an HLA-B8 antiserum, 0800 (13) . The deletion breakpoints in 8.1.6 and 9.28.6 were defined by Southern blot analyses, as described (14) . A derivative of T1, (T2) was selected for loss of both copies of human chromosome 6 provided by CEM (9) . T2 ceils expressing transfected DRA and DRBI*0408 cDNAs (T2-DR) were provided by W. Kwok. The cDNAs were introduced in retroviral vectors, as described (15) .
T Cells and T Cell Proliferation Assays.
The generation of the hepatitis B surface antigen (HBsAg)-specific T cell clone and identification of a stimulatory oligopeptide Sla (amino acid position 14-33) have been described (6) . The polyclonal T cell line specific for tetanus toxoid (TT) was generated as described (16) . The immunogenic peptide derived from tetanus toxin (amino acid position 947-969) has been described (17 Induction of HLA-B27 Cell Su~ce Expression. Cells (3 x l@/ml) were exposed to medium (RPMI 1640 plus 10% FCS) plus DMSO (0.5%) alone or medium plus DMSO and either the HLA-B27-restricted peptide of the HIV-1 gag protein (amino acids 265-279) (24) or Sla, the FILA-DP4-restricted peptide of HBsAg (amino acids 14-33), as a negative control. Both peptides were used at a concentration of 50 ~tg/ml. Incubation was for 48 h at 37~ 5 x 10 s cells were harvested and stained by indirect immunofluorescence with mAb ME-l, followed by FITC-labeled GAM. Samples were analyzed on a FACScan | (Becton Dickinson & Co.).
Dimer Stability Assay. This assay has been described (5). Briefly, unboiled, whole-cell NP-40 extracts were analyzed by onedimensional SDS-PAGE and immunoblotted with monoclonal HB10.A, which reacts with DRB chains as monomers and as DRc*/3 dimers (25) . The stability of HLA dass II dimers to SDS without boiling or reduction has been described (26) . Southern Blot Analyses. These analyses were performed as described (14) .
Results

Mutant 5.2.4 Has a Homozygous Deletion within the Class II Region of the MHC.
The progenitor of both the newly isolated mutant 5.2.4 and of the 16.23 sdected mutants (e.g., 9.5.3) was 8.1.6, which in turn was isolated from the B lymphoblastoid line T5-1 (Fig. 1 a) . 8.1.6 has a hemizygous deletion of its MHC DQ1/DR1 haplotype whose breakpoints map telomeric of the DP genes and centromeric of the C4 genes (14) . More precise mapping of the deletion breakpoints ( Fig. 1 b) demonstrates that the Xl-6 genes located immediately centromeric of the 21-OHB gene, and the Y4 and Y5 genes located telomeric of the DNA gene, lie outside the 8.1.6 deletion and thus delimit its centromeric and telomeric breakpoints (27) . Mutant 5.2.4 has undergone a second deletion, in MHC haplotype DQ2/DR3. From serological analyses (data not shown) the second ddetion appears to have removed the entire MHC of the DQ2/DR3 haplotype. This was confirmed by Southern blot analyses, which indicate that 5.2.4 has a homozygous deletion of the DR/DQ region and a hemizygous deletion of DP and class I genes ( Fig. 1 c) .
Class II-restricted Antigen Presentation Is Impaired in Mutant 5.2.4.
To evaluate the ability of 5.2.4 to present class II-restricted antigens to T cells, we studied its ability to present HBsAg to a specific, DP4-restricted T cell clone. Soluble HBsAg must be processed to yield the epitope recognized by these T cells and a synthetic peptide corresponding to amino acids 14-33 of HBsAg (Sla) is also stimulatory for this clone (6) . We compared presentation of HBsAg by 5.2.4 to that of its progenitor, 8.1.6, and to a DP-hemizygous cell line, 9.28.6 (see Fig. 1 a) , the latter to control for any effect of the DP gene dosage difference between 8.1.6 (dizygous) and 5.2.4 (hemizygous). The progenitor line, 8.1.6, and the 9.28.6 control line effectively present both native HBsAg and the synthetic peptide corresponding to the HBsAg epitope (Fig.  2 a) . In contrast, mutant 5.2.4 is defective for presentation of the native antigen, but effectively presents the HBsAg peptide. Likewise, presentation of native TT is defective in 5.2.4, whereas a DP-restricted TT peptide is presented normally (Fig. 2 a) . These results indicate that mutant 5.2.4 has a defect resembling that found in the previously characterized 16.23-selected mutants in that it is defective for presentation of intact protein antigens to class II-restricted T cells, but effectively presents the peptide epitope from those antigens.
Both 16.23 Selected Mutants and 5.2.4 Have an Enhanced Capacity to Present Peptide Antigen.
We have hypothesized that the altered conformation of cell surface class II molecules in the 16.23-selected mutants reflects reduced occupancy of their peptide-binding grooves (6) . To evaluate the possibility that the binding grooves of the DP molecules expressed by 5.2.4 are empty or under-occupied, we compared the ability of 5.2.4 and a control DP hemizygous line, 9.28.6, to stimulate a specific T cell response over a range of concentrations of peptide antigen. Mutant 5.2.4 shows an "~15-fold enhancement in HBsAg peptide presentation compared with 9.28.6 (Fig.  2 b) . Presentation by 5.2.4 of another DP-restricted peptide, amino acids 94%969 of TT, is also enhanced to a similar degree (T. Monji, data not shown). Mutants 9.5.3, 7.9.6, and 7.2.6, representative of the 16.23-selected mutants, also show enhanced presentation of the DP-restricted HBsAg peptide, compared with progenitor 8.1.6 (Fig. 2 c) . Thus, both 5,2.4 and the set of mutants represented by 9.5.3 present DPrestricted peptides more effectively than wild-type cells. These results are consistent with the hypothesis that these mutants bind class U-restricted peptides more avidly than the progenitor because the binding grooves of their class II dimers are empty or underoccupied with self-peptides.
MHC Deletion Mutant 5.2.4 Is Noncomplementary with the I6.23 Selected Mutant 9.5.3.
To evaluate the possibility that the gene responsible for the class II presentation defect in the homozygous deletion mutant 5.2.4 is the same as that altered in mutant 9.5.3, we made a somatic cell hybrid between 5.2.4 and 9.5.3 and assayed the hybrid for complementation of the mutant phenotype. To assess complementation, we examined the conformational state of the DR molecules expressed by the 5.2.4 x 9.5.3 hybrid. In two independent hybrids, the DR molecules retain the mutant phenotype: the hybrids fail to bind the 16.23 antibody (Fig. 3 a) , and extracted DR dimers from the hybrids dissociate into monomers in SDS-PAGE (Fig. 3 b) . Thus, the conformational defect in the DR molecules expressed by 9.5.3 is not restored by hybridization with 5.2.4. These hybrid cells are also impaired for presentation of intact TT, but effectively present a DPrestricted peptide derived from TT (Fig. 3 c) . By these three criteria, therefore, the hybrids made between 9.5.3 and 5.2.4 maintain the mutant phenotype. Further, as the lesions in both 9.5.3 and 5.2.4 act as recessives in somatic call hybrids (see Table 1 ), the mutant phenotype of the 9.5.3 x 5.2.4 hybrid indicates that the mutations affecting class II molecules in 9.5.3 and 5.2.4 are noncomplementary. Thus, it appears that the same gene is defective in both cells, making it likely that the relevant gene is MHC linked.
T2, a Second Homozygous MHC Deletion Mutant, Is Also Noncomplementary with 9.5.3. It was formally possible that a second mutation in 5.2.4, in addition to its MHC deletion, was responsible for the class II presentation defect in mutant 5.2.4 and for its lack of complementation with mutant 9.5.3. To address this possibility, we utilized T2, a class II-negatire, MHC deletion mutant not related to 5.2.4, but with a slightly larger homozygous deletion that includes that of 5.2.4 (references 9, 27). We first asked whether class II molecules introduced into T2 by transfection manifest the mutant phenotype. This proved to be the case; DR molecules in a T2-DR transfectant are expressed stably as dimers at the cell surface (Fig. 3 a) but dissociate into monomers in SDS-PAGE (Table 1) . Second, we made a somatic cell hybrid between mutant 9.5.3 and the T2-DR transfectant. The DR3 molecules expressed by this hybrid retain the mutant phenotype, as they fail to regain binding of the 16.23 mAb ( Table 1 ). The mutation in 9.5.3 is also recessive ( Table 1 and reference 6). The 9.5.3 x 7.2.6 hybrid, the 9.5.3 x 7.9.6 hybrid, and the 7.2.6 x 7.9.6 hybrid all retain the mutant phenotype for DR dimer stability ( Table 1 ), suggesting that these mutants constitute a single complementation group. None of these hybrids have regained normal binding of mAb 16.23 (Table 1) . It thus appears that a single, MHC-linked gene is responsible for the class II presentation-defective phenotype in mutants 9.5.3, 7.9.6, and 7.2.6.
Cell Surface Expression of Class I MHC Molecules Is Reduced in Mutant S.2.4, but Not in16.23 Selected Mutants.
AnMHClinked gene, peptide supply Factor 1 (PSF1), is implicated in the control of cell surface abundance of class I MHC molecules (27, 28) . In mutant cells that lack mRNA for this ments. Stimulation of HBsAg-specific T cells by 9.28.6 with intact protein, 29,147 cpm; with peptide, 63,654 cpm; stimulation of TT-specific T cells by 9.28.6 with intact protein, 9,305 cpm, with pepfide, 9,063 cpm. The modest T cell stimulation in response to 5.2.4 cells exposed to intact antigen may be due to the fact that the 5.2.4 mutation is "leaky;' i.e., some class II/peptide complexes form in 5.2.4, despite deletion of the relevant gene. Alternatively, the whole antigen preparations may contain small amounts of denatured or fragmented antigen which can be presented without further processing. For the polyclonal TT-specific T cell line, a third possibility is that the line includes a subpopulation of T cells responsive to complexes generated in a pathway which is unaltered in 5. gene, assembly and cell surface expression of class I molecules are defective, but can be restored by incubation with peptides that bind to the class I molecules expressed by the cell (27). Mutant 5.2.4, which is homozygously deleted for PSF1, shares this phenotype. Its surface level of HLA-A2 is reduced by ~50% (Fig. 4 a) and that of HLA-B27 is reduced by m85% compared to progenitor 8.1.6 (Fig. 4 b) . Incubation of 5.2.4 with peptides that bind to HLA-B27, HIV gag 265-279 (Fig. 4 d) , or influenza nucleoprotein 383-394 (not shown) enhances HLA-B27 cell surface expression two fold, whereas incubation with a DP-restricted peptide has no effect (Fig. 4 c) . In contrast, PSF1 function does not appear to be defective in mutants 9.5.3, 7.2.6, and 7.9.6, as evidenced by their normal cell surface levels of HLA-A2 and B27 (Fig. 4,  a and b) 
Discussion
In a previous study, we characterized a set of mutants of an EB virus-transformed B cell line that are defective in their ability to function as class II-restricted antigen-presenting cells when exposed to intact exogenous antigens (16.23-selected mutants). At that time, the genetic basis for the defect was not determined. In the present study, we have explored the genetics of the class II presentation defect using a homozygous MHC deletion mutant, 5.2.4. We were first led to investigate class II-restricted presentation in 5.2.4 because the 16.23-selected mutants arose at a high frequency (ml0 -4) in mutagenized cell line 8.1.6, which has a hemizygous MHC deletion (see Fig. 1 a) . The fact that no such mutants could be isolated from comparably mutagenized T5-1, the undeleted progenitor of 8. 4 expresses DP molecules on the cell surface, it is defective in the presentation of DP-restricted intact protein antigens to antigen-specific T cells. It presents DP-restricted antigenic peptides efficiently, however. In fact, in this study we show that both 5.2.4 and the previously isolated mutants present peptides more efficiently than does the progenitor. The enhanced presentation of peptides is consistent with the interpretation that class II molecules on the cell surface of these mutants are un-or underoccupied with self-peptides. The fact that 5.2.4 had acquired the class II presentation defect which characterizes the previously isolated mutants coincidently with a homozygous MHC deletion further implicated the deleted region as the site of the involved gene. Given the phenotypic similarities of the defects in 5.2.4 and the 16.23-selected mutants, it became of interest to determine whether defects in the same or different genes underlie the presentation abnormalities. The result is dear: 5.2.4 fails to complement three independently arising 16.23-selected mutants, and the latter fail to complement each other. This is consistent with the interpretation that all four mutants are defective in the same gene(s). Based on the complemen-tation results and the association of the class II presentation defect in 5.2.4 with the homozygous deletion in the class II region, we tentatively concluded that the affected gene in all four mutants maps to the deleted region. However, it remained possible, although unlikely, that 5.2.4 could have an occult second genetic lesion elsewhere in the genome that was responsible for its presentation defect, and that this gene was also defective in the 16-23-selected mutants. If this were the case, a second, independently arising mutant with a homozygous deletion that includes the MHC deletion in 5.2.4 should complement the class II presentation defect in the 16.23-selected mutants. T2 has a homozygous MHC deletion that includes that of 5.2.4. However, T2 failed to rescue the mutant phenotype in a hybrid between T2 and mutant 9.5.3, again consistent with the mapping of the presentation defect to the deletion. In addition, DR dimers expressed by a T2-DR transfectant demonstrate the in vitro instability characteristic of the class II mutant phenotype (Table 1) , and DR3 dimers expressed by a T2-DR3 transfectant fail to bind the 16.23 antibody (P. Cresswell, personal communication). For these reasons we conclude that a gene(s) whose defect is responsible for the class II presentation abnormality in 5.2.4 and the 16.23-selected mutants maps to the MHC class II region.
Within the 5.2.4 deletion implicated in the class II presentation defect, the only known genes, besides class II structural genes, are a cluster of genes mapping between DNA and DOB ( Fig. 1 b and reference 27) . Two of these, designated Y1 and Y3, are homologous to bacterial transport and mammalian multi-drug resistance genes. The Y3 gene product, PSF1, is required for normal cell surface abundance of class I molecules. A mutant, 721.134, which lacks Y3 mRNA, has reduced surface levels of class I molecules and is complemented for this defect by transfection of an expressible Y3 gene (27, 28) . However, a similar defect in class I molecule expression in the MHC deletion mutant 721.174 is not restored by transfection of Y3, suggesting that another gene(s) in this region is also required for normal cell surface expression of class I molecules (28) . Thus, the deletion of Y3, and possibly of this other unidentified gene(s), is likely to explain the lowered cell surface level of class I molecules in mutant 5.2.4.
Deletion of Y3 seems unlikely to explain the class II presentation defect in 5.2.4, however. The 16.23-selected mutants 9.5.3, 7.9.6, and 7.2.6 are noncomplementary with 5.2.4 for the class II presentation defect, but they have normal surface abundance of class I molecules, indicating that their Y3 genes are functioning normally. Abnormalities in the Y1 gene, which, like Y3, is homologous to transport genes, could account for the defect in class II-restricted antigen presentation in 5.2.4 and the 16.23-selected mutants. If the class II presentation defect in these mutants were caused by defects in Y1, it would suggest that class II-restricted peptides must be transported across a membrane. Other candidate genes that might be defective in the class II presentation mutants include two MHC-linked genes encoding the polymorphic subunits of an intracellular complex, low molecular weight polypeptide (LMP) (29) . The biological function of the LMP complex is unknown, but it shares some structural features k.. of the proteolytic proteosome complex (30) . A final possibility is that the relevant gene is an as yet unrecognized gene mapping to the region encompassed by the 5.2.4 deletion. Our study has demonstrated for the first time that genes within the MHC other than the classical MHC structural genes are required for class II-restricted antigen presentation. These results, taken together with the recent finding of an MHC-linked function required for dass I-restricted presentation, yield an emerging picture of striking conservation of MHC linkage of genes involved in antigen presentation.
